Key result
Zhibituo plus atorvastatin boosts overall efficacy to ~93% vs atorvastatin alone in diabetic hyperlipidemia.
Why the study?
The efficacy of zhibituo combined with atorvastatin on type 2 diabetic patients with hyperlipidemia and its impact on blood lipids, fibrinogen, and D-dimer was not well established.
Does zhibituo combined with atorvastatin improve efficacy, lipid profiles, and coagulation markers in type 2 diabetic patients with hyperlipidemia compared to atorvastatin alone?
RCT (n=170)
randomly divided
No
Does zhibituo combined with atorvastatin improve efficacy, lipid profiles, and coagulation markers in type 2 diabetic patients with hyperlipidemia compared to atorvastatin alone?
Absolute Event Rate: 92.94% vs 81.18%
p-value: p=<0.05
Zhibituo combined with atorvastatin provides superior improvements in lipid profiles, glycemic control, and coagulation markers compared to atorvastatin alone in patients with type 2 diabetes and hyperlipidemia.
May support adjunctive zhibituo with atorvastatin in diabetic hyperlipidemia; leaves open confirmation in larger randomized trials.
Objective To observe the efficacy of zhibituo combined with atorvastatin on type 2 diabetic patients with hyperlipidemia and its impact on blood lipids,fibrinogen (Fib) and D-dimer.Methods One hundred and seventy type 2 diabetic patients with hyperlipidemia visited our hospital from January 2010 to December 2012 were randomly divided into observation group and control group(with 85 cases in each group).Control group were given atorvastatin (1 0 mg,1 times / day),and the observation group were treated with zhibituo(1.05 g,3 times/day) on the basis of atorvastatin treatment,both treatment were 8 weeks.The levels of fasting plasma glucose (FPG),glycosylated hemoglobin (HbAlc),lipids,Fib and D-dimer were observed before and after treatment,and the efficacy of the two groups were compared.Results The efficacy in observation group was significantly higher than that in the control group (92.94% (79/85) vs.81.18% (69/85),x2 =4.229,P < 0.05).There was significant difference on the levels of total cholesterol (TC) ((7.46 ±1.83) mmol/L vs.(4.28 ± 1.94) mmol/L,triglycerides (TG) (3.57 ± 1.32) mmoL/L vs.(1.47 ± 0.86)mmol/L,low-density lipoprotein cholesterol (LDL-C) (4.68 ± 1.04) mmol/L vs.(2.19 ± 0.72) mmol/L,high density lipoprotein cholesterol (HDL-C) (0.85 ± 0.21) mmol/L,vs.1.47 ± 0.43) mmol/L,fasting plasma glucose (FPG) ((8.65 ± 2.19) mmol/L vs.(6.38 ± 0.83) mmol/L).glvcosvlated hemoglobin (HbAlc) ((7.49 ± 1.67)% vs.(6.28 ± 1.48)%),fibre(FiB) ((7.42 ± 1.38) mg/L vs.(3.76 ± 1.18)mg/L),and D-dimer ((1.18 ±0.17) g/L vs.(0.51 ±0.18) g/L) in observation group before and after treatment(t =10.993,12.289,18.849,11.945,8.936,4.999,18.584,24.949 respectively,all P < 0.05).And there was also significant difference on the levels ofTC ((7.51 ± 1.27) mmol/L vs.(5.10 ±2.18) mmol/L),TG((3.48 ± 1.29) mmol/L vs.(1.88 ±0.37) mmol/L),LDL-C((4.57 ± 1.18) mmol/L vs.(2.81 ±0.83) mmol/L),HDL-C ((0.83 ± 0.22) mmol/L vs.(1.16 ± 0.28) mmol/L),FPG((8.72 ± 1.92) mmol/L vs.(7.42 ± 1.82) mmol/L),HbAlc((7.53 ± 1.32)% vs.(6.79 ± 1.23)%),Fib((7.38 ± 1.63) mg/L vs.(4.41 ± 1.02) mg/L) and D-dimer ((1.20 ±0.15) g/L vs.(0.65 ±0.12) g/L) in control group before and after treatment (t =8.807,10.992,11.248,8.544,4.530,3.781,14.240,26.397,respectively,all P <0.05).The elevated levels of the observation group were more obvious compared with control group ((t =2.591,4.038,5.202,5.570,4.793,2.443,3.842,5.967 respectively,all P <0.01).Conclusion The efficacy of zhibituo combined with atorvastatin is obvious in type 2 diabetic patients with hyperlipidemia,it is helpful to regulate the disorders of fibrinolysis and coagulation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2013) conducted an RCT in Type 2 diabetes with hyperlipidemia (n=170). Zhibituo combined with atorvastatin vs. Atorvastatin 10 mg 1 times/day was evaluated on Overall efficacy (p=<0.05). Zhibituo combined with atorvastatin significantly improved overall efficacy compared to atorvastatin alone (92.94% vs 81.18%, P<0.05) in type 2 diabetic patients with hyperlipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: